Clinical Trial Update: Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of SOR-C13 in patients with advanced cancers expressing the TRPV6 channel has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SOR-C13 (SOR-C13)

Snippet

Sponsor: Soricimed Biopharma Inc | Conditions: Cancer | Phase 1 | Status: COMPLETED